Navigation Links
Hospira to Present at J.P. Morgan's 27th Annual Healthcare Conference January 14
Date:12/29/2008

LAKE FOREST, Ill., Dec. 29 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced that Christopher B. Begley, chairman and chief executive officer, and Thomas E. Werner, senior vice president, Finance, and chief financial officer, will make a formal presentation at J.P. Morgan's 27th Annual Healthcare Conference on Wednesday, Jan. 14, 2009, at The Westin St. Francis Hotel in San Francisco.

The presentation is scheduled to begin at 10 a.m. Pacific time on Wednesday, Jan. 14, 2009. It will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira's Web site at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the audiocast. The slides accompanying the presentation will be available on the Hospira Web site. A replay of the webcast will be available on the Hospira Web site approximately 24 hours after the live presentation.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
2. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
3. Hospira Reports Third-Quarter 2007 Results
4. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
5. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
6. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
7. Hospira Launches Generic Irinotecan Injection
8. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
9. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Hospira Acquires Sculptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 30, 2017 , ... Grass pollen is the main cause of hay ... the stuff. The season for grass pollen runs from May to July each year; with ... fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and ... two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, ...
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research and ... Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" ... ... 2021 from its current market size in 2016. The Untapped Proton Therapy ... than 1 Billion USD in 2016. Proton Therapy plays ...
(Date:3/29/2017)...  Zynex (OTCQB: ZYXI), an innovative medical technology company specializing ... for pain management, stroke rehabilitation, cardiac monitoring and neurological ... 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 a.m. ... expects to file its 2016 full year financial results ... ...
Breaking Medicine Technology: